InvestorWire NewsRoom

Article

Lexaria Bioscience Corp. (NASDAQ: LEXX) Targets Burgeoning Hypertension, Antiviral Therapeutics Markets with Drug Delivery Technology
September 1, 2021

Lexaria Bioscience Corp. (NASDAQ: LEXX) Targets Burgeoning Hypertension, Antiviral Therapeutics Markets with Drug Delivery Technology

  • Lexaria has progressed significantly in evidencing that its patented DehydraTECH(TM) drug delivery technology can sufficiently improve the usable fraction of known antiviral drugs that reach the bloodstream
  • According to a Newsfile Corp. article, this technology can be applied to rendering treatments for HIV/AIDS and other infectious diseases more effective
  • The company also released partial results from a human clinical study evaluating DehydraTECH-processed CBD for potential application against hypertension, which evidenced a rapid and sustained drop in blood pressure
  • Growing hypertension and antiviral therapeutics market represent a potential win for Lexaria

In July, Lexaria Bioscience (NASDAQ: LEXX), a drug delivery technology developer, issued several key announcements that, in addition to highlighting the progress made in advancing its patented DehydraTECH(TM) drug delivery technology, form the basis of analysis in a recent Newsfile Corp. article (https://ibn.fm/1BOgg). 

On July 22, the Kelowna-based global innovator reviewed its successful 2021 antiviral drug program. With diseases caused by viruses, including HIV/AIDS, influenza, and, more recently, COVID-19, having made the demand and need for effective antiviral drugs via oral delivery that are available to all more profound than ever before, Lexaria has made strides. The company has progressed significantly in evidencing that DehydraTECH can sufficiently enhance the usable fraction of known antiviral drugs that reach the bloodstream to safely and more effectively do what they are designed to accomplish. Still, it continues to evaluate the data generated from the program (https://ibn.fm/MQIDe).

According to the Newsfile article, the antivirals represent a much broader market for DehydraTECH, especially currently, because in response to COVID-19, they “are having a moment.” Even so, “the same technology can be applied to rendering treatments for AIDS and other infectious diseases more effective. Antihistamines and anti-inflammatory drugs, as well as such therapeutics as remdesivir, have all been shown to be enhanced by DehydraTECH in animal studies,” the article notes.

Lexaria is likely to benefit from the projected growth in the global antiviral therapeutics market, which is expected to surge to $67.76 billion in 2026 from $51.26 billion in 2020, representing a 4.76% CAGR. Analysts at Mordor Intelligence peg this growth on robust R&D investment in antiviral drugs by public and private companies (https://ibn.fm/NbkIA). 

Notably, the antiviral program is just one of several others Lexaria is focusing on at present. Another applied R&D program, which also featured prominently in the Newsfile article, is hypertension. On July 29, the company released partial results from a human clinical study, HYPER-H21-1, evaluating DehydraTECH-processed cannabidiol (“CBD”) for potential application against hypertension (https://nnw.fm/9WvGd). (https://cnw.fm/rYTu4). (https://ibn.fm/fmGyE). 

The study revealed a rapid and sustained drop in blood pressure with DehydraTECH-processed CBD and was most pronounced within the first 10 to 50 minutes of the study. This evidence reinforced the company’s pre-existing findings and further demonstrated that its drug delivery technology offers superior performance over generic CBD controls (https://ibn.fm/eYP1p). 

“That CBD would be among the first use cases for such a platform as DehydraTECH makes sense,” reads the Newsfile article, “FDA-approved for pediatric seizure purposes since 2018, it has gained a great deal of traction over a short period of time. While its most closely identified delivery vector is hemp cigarettes, these can damage lungs as much as pills can damage livers.”

The article further notes that hypertension represents a new market for CBD and a potential huge win for Lexaria. Valued at $27.8 billion in 2018, the antihypertensive drug market is expected to grow at a CAGR of about 2% from 2019 to 2027 (https://ibn.fm/eMoJz).

On July 28, Lexaria announced that DehydraTECH is available for sale in more than 7,000 stores across the US, in what CEO Chris Bunka noted was an indication that the delivery technology is enabling increased market share and sales growth for its expanding list of corporate clients (https://ibn.fm/U4ws7). 

The article also highlights Lexaria’s financial information. “Its balance sheet is clean, but that is in large part due to Lexaria’s ability to raise money on financial markets. Earnings are not what one would hope for, and yet the market cap is roughly 10x assets, suggesting high confidence in management,” it concludes. 

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).